Buy & Sell ADMA Biologics Inc (ADMA) – ADMA Biologics Inc Price Today
Aura AI Summary
Key Stats
- $2.02BMarket Cap
- HealthSector
- -32.5%3M Drawdown
- $2.09BEnterprise Value
- -Dividend Yield
- 100% Buy | 0% SellTrading Activity
- 11 daysTypical Hold Time
ADMA Biologics Inc (ADMA) is currently valued at a market capitalization of $2.02B, with an enterprise value of $2.09B. Over the past 52 weeks, ADMA Biologics Inc has traded between a low of $7.6 and a high of $20.38, highlighting its annual price range. Over the past three months, ADMA Biologics Inc has recorded a drawdown of -32.5%, reflecting recent price volatility. On average, investors hold ADMA Biologics Inc for approximately 11 days, indicating typical investor behavior on the platform.
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Most Recent News
Investors in Putnam mutual funds may claim compensation over alleged misleading info by Putnam Investment Management.
The Rosen Law Firm has announced an investigation into Putnam Investment Management, LLC for potentially issuing misleading business information to investors in its stock-based mutual funds. Investors who purchased these funds might be eligible for c...

Investors in Strategy Inc. may claim compensation over alleged misleading info in securities.
The Rosen Law Firm has announced an investigation into potential securities claims for shareholders of Strategy Inc. due to allegations that the company provided materially misleading business information. Investors who purchased Strategy securities ...

Ulta Beauty shares drop 20% YTD despite strong sales, creating a value buying opportunity.
Ulta Beauty's stock has fallen about 20% year-to-date, even though the company continues to show strong sales growth and gains in market share. This decline is largely due to investors rotating capital away from mega-cap tech stocks, which has left r...
